Reduced adrenal stress response in patients on PCSK9 inhibitor therapy-Reference-Cited by-同舟云学术

Reduced adrenal stress response in patients on PCSK9 inhibitor therapy

Published:2021-05 Issue: Volume:325 Page:63-68
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Meier Simon,Frick Marcel,Liu Michael,Saeedi Saravi Seyed Soheil,Montrasio Giulia,Preiss Helga,Pasterk Lisa,Bonetti Nicole,Egloff Michael,Schmid Hans-Rudolf,Sudano Isabella,Camici Giovanni G.,Mach François,Luescher Thomas F.,Ehret Georg,Beer Jürg H.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy;McKenney;J. Am. Coll. Cardiol.,2012

2. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia;Roth;N. Engl. J. Med.,2012

3. Efficacy and safety of alirocumab n reducing lipids and cardiovascular events;Robinson;N. Engl. J. Med.,2015

4. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N. Engl. J. Med.,2017

5. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N. Engl. J. Med.,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meet the Editorial Board Member;Anti-Cancer Agents in Medicinal Chemistry;2022-04

2. Insight into the Evolving Role of PCSK9;Metabolites;2022-03-17

3. Side effects of anti-lipid medications;Side Effects of Drugs Annual;2022